Fludara®
Company
Schering AG
Use
Treatment of chronic lymphocytic leukemia (CLL) for patients who did not respond to alkylating agents
Features
First treatment in a new class of highly effective chemotherapy agents (the purine analogues) for chronic lymphocytic leukemia
NIH Contribution
Synthesis and use of fludarabine for cancer
Approval Type
FDA
HHS Institute/Agency
NCI
Inventor(s)
J. Montgomery
Year
1991
Tech Cat
Therapeutic
Request More Info
